First Nasal spray to treat Covid-19 launched in India. Check out details here

First nasal spray to treat Covid-19 in adults is here. Pharma company Glenmark has launched Nitric Oxide Nasal Spray, called FabiSpray in India, in partnership with SaNOtize.

The makers say that the spray will treat adult patients suffering from Covid-10, news agency ANI has reported.

Glenmark received manufacturing and marketing approval from India's drug regulator for Nitric Oxide Nasal Spray as part of the accelerated approval process.

The company said that phase 3 trial in India demonstrated reduction of viral load by 94 per cent in 24 hours and 99 per cent in 48 hours.
"Nitric Oxide Nasal Spray was safe and well-tolerated in Covid-19 patients," an official statement said.

The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.

"FabiSpray is designed to kill the Covid-19 virus in the upper airways. When sprayed over nasal mucosa, it acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs," the statement said.

Terming the spray an effective and safe antiviral treatment for Covid-19, Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart said "we are confident it will offer patients a much needed and timely therapy option."